Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its holdings in DaVita Inc. (NYSE:DVA – Get Rating) by 18.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 40,343 shares of the company’s stock after purchasing an additional 6,187 shares during the quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s holdings in DaVita were worth $3,019,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors have also recently added to or reduced their stakes in DVA. Captrust Financial Advisors raised its position in shares of DaVita by 3.7% during the 1st quarter. Captrust Financial Advisors now owns 3,860 shares of the company’s stock worth $437,000 after purchasing an additional 139 shares during the period. Parkside Financial Bank & Trust raised its position in shares of DaVita by 88.6% during the 1st quarter. Parkside Financial Bank & Trust now owns 313 shares of the company’s stock worth $35,000 after purchasing an additional 147 shares during the period. Wetherby Asset Management Inc. raised its position in shares of DaVita by 8.1% during the 1st quarter. Wetherby Asset Management Inc. now owns 2,050 shares of the company’s stock worth $232,000 after purchasing an additional 154 shares during the period. CIBC Asset Management Inc raised its position in shares of DaVita by 1.7% during the 3rd quarter. CIBC Asset Management Inc now owns 9,555 shares of the company’s stock worth $791,000 after purchasing an additional 163 shares during the period. Finally, Comerica Bank raised its position in shares of DaVita by 2.3% during the 4th quarter. Comerica Bank now owns 8,360 shares of the company’s stock worth $661,000 after purchasing an additional 187 shares during the period. 86.52% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Several analysts recently commented on DVA shares. Truist Financial raised their target price on DaVita from $84.00 to $90.00 and gave the company a “hold” rating in a research report on Thursday, February 23rd. Cowen raised their target price on DaVita from $76.00 to $90.00 and gave the company an “outperform” rating in a research report on Thursday, February 23rd. Sanford C. Bernstein started coverage on DaVita in a research report on Tuesday, March 7th. They issued a “market perform” rating on the stock. Deutsche Bank Aktiengesellschaft raised their target price on DaVita from $72.00 to $85.00 in a research report on Thursday, February 23rd. Finally, StockNews.com started coverage on DaVita in a research report on Thursday, March 16th. They issued a “buy” rating on the stock. One analyst has rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the company. According to data from MarketBeat, DaVita presently has a consensus rating of “Hold” and a consensus price target of $86.43.
DaVita Stock Performance
DaVita (NYSE:DVA – Get Rating) last released its quarterly earnings data on Wednesday, February 22nd. The company reported $1.11 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.23. The business had revenue of $2.92 billion during the quarter, compared to analyst estimates of $2.93 billion. DaVita had a return on equity of 74.02% and a net margin of 4.83%. The company’s revenue was down .9% compared to the same quarter last year. During the same period last year, the company posted $2.02 EPS. Research analysts forecast that DaVita Inc. will post 5.93 EPS for the current fiscal year.
Insider Transactions at DaVita
In other news, Director Charles Berg sold 1,431 shares of the firm’s stock in a transaction on Thursday, March 9th. The stock was sold at an average price of $75.13, for a total transaction of $107,511.03. Following the completion of the sale, the director now directly owns 15,733 shares of the company’s stock, valued at approximately $1,182,020.29. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.00% of the company’s stock.
DaVita Company Profile
DaVita, Inc engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure.
See Also
- Get a free copy of the StockNews.com research report on DaVita (DVA)
- It’s Time To Check Into Booking.Com
- Shopify Delivers Growth And Efficiency; Shares Surge
- Advanced Micro Devices Bullish Reversal Is Still In Play
- Broadcom Shares Trade In Tight Range Ahead Of Q2 Earnings Report
- An Opportunity To Buy Starbucks Is Knocking On The Door
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.
